- Matthew Gallagher launched telehealth startup Medvi with $20,000 and a stack of AI tools, reaching $401 million in revenue in its first year and projecting $1.8 billion in annual sales.
- Gallagher used ChatGPT, Claude, and Grok for code generation, Midjourney and Runway for ad creatives, and ElevenLabs for customer service automation.
- Medvi sells GLP-1 drugs online, outsourcing doctors, prescriptions, and shipping to telehealth platforms CareValidate and OpenLoop.
- The company operates with only two full-time employees: Gallagher and his brother, with AI handling functions that would typically require dozens of staff.
What Happened
Matthew Gallagher built and scaled a telehealth startup called Medvi from a $20,000 initial investment to $1.8 billion in projected annual sales, using commercially available AI tools to replace nearly every function that would traditionally require a full corporate workforce. The story was reported by The Rundown AI on April 3, 2026, citing a profile published by The New York Times. Gallagher’s trajectory positions him as one of the first founders to validate a prediction that OpenAI CEO Sam Altman made in 2024: that AI would make the solo billion-dollar company possible.
Medvi sells GLP-1 weight loss drugs, including medications related to the popular Ozempic and Wegovy brands, through an online platform. Rather than building medical infrastructure in-house, Gallagher outsources doctors, prescriptions, and shipping logistics to established telehealth platforms CareValidate and OpenLoop. The entire operation took approximately two months to build from scratch.
Why It Matters
Gallagher’s case provides a concrete data point in the ongoing debate about whether AI tools can fundamentally change the economics of starting and scaling a company. When Sam Altman made his prediction in 2024 about AI enabling solo billion-dollar companies, many observers treated it as aspirational marketing language from an AI company CEO. Medvi’s trajectory, from $20,000 in startup costs to $401 million in first-year revenue and a projected $1.8 billion in its second year, suggests the prediction was not entirely speculative, at least in industries where AI can simultaneously automate customer acquisition, content creation, and customer service.
The case is notable because Gallagher did not build novel AI technology. Instead, he treated commercially available AI tools as an operational substitute for the marketing, engineering, design, and customer service teams that a traditional company of Medvi’s revenue scale would employ. This approach positions him not as a technology innovator but as a business operator who leveraged existing AI capabilities more aggressively than most founders have attempted, reducing fixed labor costs to near zero while maintaining the ability to scale revenue rapidly.
Technical Details
Gallagher’s AI tool stack spans multiple operational categories. He used ChatGPT, Claude, and Grok for code generation and business logic development, effectively replacing a software engineering team. Midjourney and Runway handled advertising creative production, generating the visual assets and video content that would typically require a creative agency or a multi-person in-house design team. ElevenLabs provided voice AI for customer service automation, and custom AI agents built on top of these platforms handled additional customer interactions that would normally require a call center or support staff.
The business model itself relies heavily on outsourcing the regulated portions of the operation. CareValidate and OpenLoop provide the medical infrastructure, including licensed physicians who write prescriptions and telehealth consultation platforms that comply with healthcare regulations. Shipping and pharmaceutical fulfillment are also handled by third-party providers. This architecture means Medvi operates primarily as a marketing and customer acquisition engine, which is precisely the category of business function where current-generation AI tools have proven most effective at replacing human labor.
Gallagher brought on his brother as the only other full-time employee. The company’s lean two-person structure means its operating margins are substantially higher than competitors like Hims & Hers or Ro that maintain payrolls of hundreds or thousands of employees, though this structure also creates operational concentration risk if key AI services experience outages, pricing changes, or policy modifications that affect Medvi’s workflows.
Who’s Affected
The telehealth industry faces a potential disruption if Medvi’s operational model proves replicable by other entrepreneurs. Established telehealth companies that employ large workforces may face margin pressure from AI-native competitors that can match their revenue output with minimal staffing. The GLP-1 drug market, which has seen explosive consumer demand, provides a favorable environment for high-volume online distribution models, though regulatory scrutiny of online pharmaceutical sales is also increasing. Workers in marketing, customer service, and creative production may view Medvi as a concrete example of how current AI tools can reduce headcount requirements in these functions.
What’s Next
Medvi’s long-term sustainability will depend on whether its growth trajectory can continue as the GLP-1 market matures, competition intensifies, and regulatory scrutiny of online drug distribution increases. The company’s reliance on a small number of AI tools and outsourced medical platforms creates dependencies that could become vulnerabilities if any single provider changes its terms, pricing, or policies. Other entrepreneurs are likely to attempt to replicate Gallagher’s approach in adjacent markets, testing whether the AI-powered minimal-employee company model extends beyond telehealth into other industries with high-margin, digitally distributable products and services.
